📣 VC round data is live. Check it out!

Co-Diagnostics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Co-Diagnostics and similar public comparables like Nestmedic, Bio-Gate, Sds Optic, Bluelinea and more.

Co-Diagnostics Overview

About Co-Diagnostics

Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.


Founded

2013

HQ

United States

Employees

115

Financials (LTM)

Revenue: $622K
Net Income: ($47M)

Market Cap

$9M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Co-Diagnostics Financials

Co-Diagnostics reported last 12-month revenue of $622K.

In the same LTM period, Co-Diagnostics generated had net loss of ($47M).

Revenue (LTM)


Co-Diagnostics P&L

In the most recent fiscal year, Co-Diagnostics reported revenue of $622K and EBITDA of ($30M).

Co-Diagnostics is unprofitable as of last fiscal year, with gross margin of 64%, EBITDA margin of (4848%), and net margin of (7534%).

See analyst estimates for Co-Diagnostics
LTMLast FY202320242025202620272028
Revenue$622K$622K$7M$4M$622K
Gross Profit$400K$3M$3M$400K
Gross Margin64%39%74%64%
EBITDA($30M)($41M)($39M)($30M)
EBITDA Margin(4848%)(609%)(989%)(4848%)
EBIT Margin(5026%)(627%)(1024%)(5026%)
Net Profit($47M)($47M)($35M)($38M)($47M)
Net Margin(7534%)(7534%)(519%)(961%)(7534%)

Financial data powered by Morningstar, Inc.

Co-Diagnostics Stock Performance

Co-Diagnostics has current market cap of $9M.

Market Cap Evolution


Co-Diagnostics' stock price is $2.53.

Co-Diagnostics share price increased by 63.2% in the last 30 days.

Co-Diagnostics has an EPS (earnings per share) of $-13.02.

See more trading valuation data for Co-Diagnostics
Market CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$9M0.0%63.2%10.0%$-13.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Co-Diagnostics Valuation Multiples

Co-Diagnostics trades at (2.5x) EV/Revenue multiple, and 0.1x EV/EBITDA.

See NTM and 2027E valuation multiples for Co-Diagnostics

EV / Revenue (LTM)


Co-Diagnostics Financial Valuation Multiples

As of May 10, 2026, Co-Diagnostics has market cap of $9M.

Co-Diagnostics has a P/E ratio of (0.2x).

LTMLast FY202320242025202620272028
EV/Revenue(2.5x)(2.5x)(0.2x)(0.4x)(2.5x)
EV/EBITDA0.1x0.0x0.0x0.1x
EV/EBIT0.0x0.0x0.0x0.0x
EV/Gross Profit(3.8x)(0.6x)(0.5x)(3.8x)
P/E(0.2x)(0.2x)(0.3x)(0.2x)(0.2x)
EV/FCF0.1x0.1x0.1x0.1x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Co-Diagnostics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Co-Diagnostics Margins & Growth Rates

In the most recent fiscal year, Co-Diagnostics reported gross margin of 64%, EBITDA margin of (4848%), and net margin of (7534%).

See estimated margins and future growth rates for Co-Diagnostics

Co-Diagnostics Margins

Last FY20242025202720282029
Gross Margin64%74%64%
EBITDA Margin(4848%)(989%)(4848%)
EBIT Margin(5026%)(1024%)(5026%)
Net Margin(7534%)(961%)(7534%)
FCF Margin(4793%)(764%)(4793%)

Co-Diagnostics Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(43%)(84%)
Gross Profit Growth11%(86%)
EBITDA Growth(7%)(22%)
EBIT Growth(6%)(22%)
Net Profit Growth7%25%
FCF Growth28%(0%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Co-Diagnostics Operational KPIs

Co-Diagnostics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.3M for the same period.

Access forward-looking KPIs for Co-Diagnostics
Last FY202320242025202620272028
Revenue per Employee$0.0M
Opex per Employee$0.3M
S&M Expenses to Revenue383%101%115%383%
G&A Expenses to Revenue1455%210%413%1455%
R&D Expenses to Revenue3074%337%536%3074%
Opex to Revenue5090%665%1098%5090%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Co-Diagnostics Competitors

Co-Diagnostics competitors include Nestmedic, Bio-Gate, Sds Optic, Bluelinea, iXensor, Subgen AI, Neola Medical, AMA Corp, PharmaCyte Biotech and Zynex.

Most Co-Diagnostics public comparables operate across Medical Devices, Laboratory Services, HealthTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Nestmedic32.6x(10.3x)
Bio-Gate1.0x0.9x(5.3x)(12.1x)
Sds Optic44.2x(25.0x)
Bluelinea1.0x16.6x
iXensor9.7x(6.6x)
Subgen AI0.6x(13.4x)
Neola Medical8.7x8.6x(7.7x)(7.5x)
AMA Corp2.7x(1.1x)

This data is available for Pro users. Sign up to see all Co-Diagnostics competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Co-Diagnostics

When was Co-Diagnostics founded?Co-Diagnostics was founded in 2013.
Where is Co-Diagnostics headquartered?Co-Diagnostics is headquartered in United States.
How many employees does Co-Diagnostics have?As of today, Co-Diagnostics has over 115 employees.
Who is the CEO of Co-Diagnostics?Co-Diagnostics' CEO is Dwight H Egan.
Is Co-Diagnostics publicly listed?Yes, Co-Diagnostics is a public company listed on Nasdaq.
What is the stock symbol of Co-Diagnostics?Co-Diagnostics trades under CODX ticker.
When did Co-Diagnostics go public?Co-Diagnostics went public in 2017.
Who are competitors of Co-Diagnostics?Co-Diagnostics main competitors include Nestmedic, Bio-Gate, Sds Optic, Bluelinea, iXensor, Subgen AI, Neola Medical, AMA Corp, PharmaCyte Biotech, Zynex.
What is the current market cap of Co-Diagnostics?Co-Diagnostics' current market cap is $9M.
What is the current revenue of Co-Diagnostics?Co-Diagnostics' last 12 months revenue is $622K.
What is the current EV/Revenue multiple of Co-Diagnostics?Current revenue multiple of Co-Diagnostics is (2.5x).
Is Co-Diagnostics profitable?No, Co-Diagnostics is not profitable.
What is the current net income of Co-Diagnostics?Co-Diagnostics' last 12 months net income is ($47M).
How many companies Co-Diagnostics has acquired to date?Co-Diagnostics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Co-Diagnostics has invested to date?Co-Diagnostics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Co-Diagnostics

Lists including Co-Diagnostics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial